Baseline hypointense somatotroph adenomas show a better response to SSA, whereas hypointensity was related to DA resistance in female prolactinomas.

No abstract

Subacute thyroiditis(SAT) developed after SARS-CoV-2 vaccines has been less studied. We aimed to compare classical SAT and SAT developed after SARS-CoV-2 vaccines in the context of clinical aspects. Adults with SAT detected in 90 days of COVID-19 vaccination (CoronaVac® or Pfizer/BioNTech®) were grouped as Vac-SAT (CoronaVac-SAT and BioNTech-SAT). Those with a history of SARS-CoV-2 or upper respiratory tract infection in 6 months before the vaccination, or vaccination with another antiviral vaccine after COVID-19 vaccination were excluded. Those with SAT detected before COVID-19 pandemic were grouped as Classical-SAT. Of total(n=85), female/male(54/31) ratio and age(43(23-65)) were similar in Vac-SAT(n=23) and Classical-SAT(n=62) groups. Duration between vaccine and SAT was 45(7-90) days, and similar in CoronaVac-SAT(n=5) and BioNTech-SAT(n=18) groups. SAT-duration was 28(10-150) days, and higher in Vac-SAT than in Classical-SAT group(p=0.023). SAT was developed after the 1st dose vaccine in minority in CoronaVac-SAT(n=2) and BioNTech-SAT(n=3) groups(p=0.263). Previous LT4 use, and TSH elevation after resolution were more frequent in Vac-SAT than in Classical-SAT(p=0.027 and p=0.041, respectively). We included a considerable number of patients with SAT occurred after COVID-19 vaccines. We cannot provide clear evidence regarding the association of COVID-19 vaccines with SAT. SAT associated with CoronaVac® or BioNTech® seems unlikely to be occurred after the 1st dose, and to have a longer duration, more likely to be associated with previous LT4 use and lead TSH elevation after resolution than Classical-SAT. TSH should be followed-up after the resolution of SAT detected after COVID-19 vaccination.

Introduction: The COVID-19 pandemic led to a lockdown period. Confinement periods have been related to unhealthy lifestyle behaviors. Our study aimed to determine weight change, changes in eating and exercise habits, the presence of depression and anxiety, and diabetes mellitus (DM) status in a cohort of patients with obesity. Methods: The study was undertaken in nine centers of Collaborative Obesity Management (COM) of the European Association for the Study of Obesity (EASO) in Turkey. An e-survey about weight change, eating habits, physical activity status, DM status, depression, and anxiety was completed by patients. The International Physical Activity Questionnaire (IPAQ) score was used to determine physical activity in terms of metabolic equivalents (METs). A healthy nutrition coefficient was calculated from the different categories of food consumption. The Patient Health Questionaire (PHQ-9) and General Anxiety Disorder (GAD-7) were used for determining depression and anxiety, respectively. Results: Four hundred twenty-two patients (age 45±12.7 years, W/M=350/72) were included. The healthy nutrition coefficient before the pandemic was 38.9±6.2 and decreased to 38.1±6.4 during the pandemic (p<0.001). Two hundred twenty-nine (54.8%) patients gained weight, 54 (12.9%) were weight neutral, and 135 (32.3%) lost weight. Patients in the weight loss group had higher MET scores and higher healthy nutrition coefficients compared with the weight gain and weight-neutral groups (p<0.001). The PHQ and GAD scores were not different between the groups. Percent weight loss was related to healthy nutrition coefficient〈CI: 0.884 (0.821-0.951), p=0.001〉 and MET categories 〈CI: 0.408 (0.222-0.748), p=0.004〉. One hundred seventy patients had DM. Considering glycemic control, only 12 (8.4%) had fasting blood glucose <100 mg/dL and 36 (25.2%) had postprandial BG <160 mg/dL. When patients with and without DM were compared in terms of dietary compliance, MET category, weight loss status, PHQ scores, and GAD scores, only MET categories were different; 29 (11.7%) of patients in the nondiabetic group were in the highly active group compared with 5 (2.9%) in the diabetic group. Conclusion: The COVID-19 lockdown resulted in weight gain in about half of our patients, which was related to changes in physical activity and eating habits. Patients with DM who had moderate glycemic control were similar to the general population in terms of weight loss but were less active.

No abstract